Moleculin Biotech, Inc.
MBRXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMoleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. The company carries a $6.6M market cap, placing it firmly in the micro-cap category. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.
Market Cap
$6.6M
Beta
2.00
P/E (TTM)
0.03
P/E (Fwd)
-0.06
EPS (TTM)
$196.20
EPS (Fwd)
$-110.50
ROE
-1371.6%
ROA
-84.6%
Cash
$7.3M
Total Debt
$292,000
Free CF
-$14.9M
52W Change
-97.3%
Annual Financials
Cash vs Debt
Where MBRX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, MBRX finished 84.80% below its 150-day moving average ($34.61) and 87.96% below its 200-day moving average ($43.68). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MBRX overbought or oversold?
At the October 20, 2026 close, MBRX's RSI(14) was 12.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $7.3M in cash and $292K in debt, MBRX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$14.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -1371.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta above 1.5, MBRX tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, MBRX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Moleculin Biotech, Inc. and its sector.